Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 2/20 | 0.40 |
| ▸ | CCKAR | P32238 | 3/20 | 0.40 |
| ▸ | CCKBR | P32239 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714337 | 0.91 | CCKAR (0.40) | CCKARCCKBRALDH1A1ADRB2HTT | |
| SCHEMBL6707635 | 0.89 | CCKAR (0.38) | CCKARCCKBRALDH1A1ADRB2HTT | |
| SCHEMBL6714114 | 0.88 | ALOX15 (0.45) | NHERF1LMNASMN1; SMN2 | |
| SCHEMBL6713077 | 0.87 | MEN1 (0.40) | NHERF1 | |
| SCHEMBL6708820 | 0.86 | PARP14 (0.41) | NHERF1ALDH1A1LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL6710319 | 0.86 | CHRNB2 (0.43) | NHERF1HTT | |
| SCHEMBL6710216 | 0.86 | KCNMA1 (0.46) | NHERF1LMNAHTT | |
| SCHEMBL6709040 | 0.86 | HDAC3 (0.40) | NHERF1 | |
| SCHEMBL6713754 | 0.86 | SERPINE1 (0.43) | NHERF1KDM4E | |
| SCHEMBL6713646 | 0.85 | NHERF1 (0.40) | NHERF1CCKARCCKBRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | NHERF1 1641/4885CCKAR 3935/4885CCKBR 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.